Antipsychotics
Psychiatry· 4 reviewed drugs· 4409 cited findings behind them
What the regulatory reviews cover
The Antipsychotics in this library include Caplyta, Vraylar, Uzedy, and Nuplazid. These drugs have been reviewed for various indications, including depressive episodes associated with bipolar I or II disorder, major depressive disorder (as adjunctive therapy), schizophrenia, and psychosis associated with Parkinson’s disease.
Regulatory reviews for these antipsychotics report a range of outcomes. For Caplyta, the MADRS Total Score LS mean difference vs placebo was -4.6. Vraylar showed a MADRS placebo-subtracted change of -1 to -2.5. Uzedy demonstrated a Hazard ratio (TV-46000 q1m vs placebo) for time to impending relapse of 0.200. Nuplazid reported an Improvement in psychotic symptoms over placebo (SAPS-PD) of 23.1. It is important to note that these figures are derived from different studies and trials, and therefore are not directly comparable head-to-head.
The drugs — one cited result each
| Caplyta Johnson & Johnson | MADRS Total Score LS mean difference vs placebo: -4.6 Johnson & Johnson — Caplyta FDA Review (NDA209500, SUPPL 6), p.48 |
| Vraylar AbbVie Inc. | MADRS placebo-subtracted change: -1 to -2.5 AbbVie Inc. — Vraylar FDA Review (NDA204370, SUPPL 9, 2022), p.69 |
| Uzedy Teva Pharmaceutical Industries Limited | Hazard ratio (TV-46000 q1m vs placebo) for time to impending relapse: 0.200 Uzedy FDA Review, p.185 |
| Nuplazid ACADIA Pharmaceuticals Inc. | Improvement in psychotic symptoms over placebo (SAPS-PD): 23.1 ACADIA Pharmaceuticals Inc. — Nuplazid FDA Review (NDA207318, p.14 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Psychiatry research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.